| TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ... Nature 554 (7693), 544-548, 2018 | 3822 | 2018 |
| Pembrolizumab as second-line therapy for advanced urothelial carcinoma J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ... New England Journal of Medicine 376 (11), 1015-1026, 2017 | 3219 | 2017 |
| Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy L Fong, Y Hou, A Rivas, C Benike, A Yuen, GA Fisher, MM Davis, ... Proceedings of the National Academy of Sciences 98 (15), 8809-8814, 2001 | 1475 | 2001 |
| Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients PP Lee, C Yee, PA Savage, L Fong, D Brockstedt, JS Weber, D Johnson, ... Nature medicine 5 (6), 677-685, 1999 | 1375 | 1999 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1045 | 2018 |
| Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory M Poggio, T Hu, CC Pai, B Chu, CD Belair, A Chang, E Montabana, ... Cell 177 (2), 414-427. e13, 2019 | 1008 | 2019 |
| Dendritic cells in cancer immunotherapy L Fong, EG Engleman Annual review of immunology 18 (1), 245-273, 2000 | 998 | 2000 |
| Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer … BI Rini, V Weinberg, L Fong, S Conry, RM Hershberg, EJ Small Cancer: Interdisciplinary International Journal of the American Cancer …, 2006 | 904 | 2006 |
| Systemic immunity is required for effective cancer immunotherapy MH Spitzer, Y Carmi, NE Reticker-Flynn, SS Kwek, D Madhireddy, ... Cell 168 (3), 487-502. e15, 2017 | 843 | 2017 |
| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 648 | 2018 |
| Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer DY Oh, SS Kwek, SS Raju, T Li, E McCarthy, E Chow, D Aran, A Ilano, ... Cell 181 (7), 1612-1625. e13, 2020 | 508 | 2020 |
| Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior … CJ Ryan, MR Smith, L Fong, JE Rosenberg, P Kantoff, F Raynaud, ... Journal of clinical oncology 28 (9), 1481, 2010 | 500 | 2010 |
| Dendritic cells injected via different routes induce immunity in cancer patients L Fong, D Brockstedt, C Benike, L Wu, EG Engleman The Journal of Immunology 166 (6), 4254-4259, 2001 | 497 | 2001 |
| A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer EJ Small, NS Tchekmedyian, BI Rini, L Fong, I Lowy, JP Allison Clinical Cancer Research 13 (6), 1810-1815, 2007 | 461 | 2007 |
| Improved survival with T cell clonotype stability after anti–CTLA-4 treatment in cancer patients E Cha, M Klinger, Y Hou, C Cummings, A Ribas, M Faham, L Fong Science translational medicine 6 (238), 238ra70-238ra70, 2014 | 432 | 2014 |
| Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 years of follow-up Y Fradet, J Bellmunt, DJ Vaughn, JL Lee, L Fong, NJ Vogelzang, ... Annals of Oncology 30 (6), 970-976, 2019 | 400 | 2019 |
| Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients F Moltzahn, AB Olshen, L Baehner, A Peek, L Fong, H Stöppler, J Simko, ... Cancer research 71 (2), 550-560, 2011 | 389 | 2011 |
| Anti–cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment L Fong, EJ Small Journal of clinical oncology 26 (32), 5275-5283, 2008 | 375 | 2008 |
| Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy L Fong, D Brockstedt, C Benike, JK Breen, G Strang, CL Ruegg, ... The Journal of Immunology 167 (12), 7150-7156, 2001 | 375 | 2001 |
| Phase II study of the anti-cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer KY Chung, I Gore, L Fong, A Venook, SB Beck, P Dorazio, PJ Criscitiello, ... Journal of Clinical Oncology 28 (21), 3485-3490, 2010 | 344 | 2010 |
